Publikationen in Zusammenarbeit mit Forschern von Hospital Arnau de Vilanova (31)

2023

  1. Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis

    Brain Communications, Vol. 5, Núm. 2

  2. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

    Multiple Sclerosis Journal, Vol. 29, Núm. 14, pp. 1808-1818

  3. Mitochondrial Aconitase Enzymatic Activity: A Potential Long-Term Survival Biomarker in the Blood of ALS Patients

    Journal of Clinical Medicine, Vol. 12, Núm. 10

  4. Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

    Frontiers in immunology, Vol. 13, pp. 842354

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  3. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

    Multiple Sclerosis and Related Disorders, Vol. 63

2021

  1. Abnormal sleep behavior caused by hypoglycemia

    Sleep Medicine, Vol. 85, pp. 268-270

  2. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement

    Neurologia, Vol. 36, Núm. 1, pp. 50-60

2017

  1. Psychometric properties of the SDM-Q-9 questionnaire for shared decision-making in multiple sclerosis: Item response theory modelling and confirmatory factor analysis

    Health and Quality of Life Outcomes, Vol. 15, Núm. 1

2016

  1. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses

    Multiple Sclerosis, Vol. 22, Núm. 1, pp. 117-121

  2. Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67)

    Journal of Neuroimmunology, Vol. 300, pp. 15-17

2015

  1. Review of the novelties from the 2014 ECTRIMS-ACTRIMS joint congress, presented at the 7th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 61, Núm. 6, pp. 271-283

  2. Review of the novelties from the 2014 ectrims-actrims joint congress, presented at the 7th post-ectrims meeting (i)

    Revista de Neurologia, Vol. 61, Núm. 5, pp. 215-224

  3. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses

    Multiple Sclerosis Journal, Vol. 21, Núm. 5, pp. 646-650

2014

  1. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS

    Multiple Sclerosis Journal, Vol. 20, Núm. 6, pp. 717-725

  2. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)

    Revista de Neurologia, Vol. 59, Núm. 7, pp. 307-316

  3. Revisión de las novedades presentadas en el XXIX congreso del comité Europeo para el tratamiento e investigación en esclerosis múltiple (ECTRIMS) (III)

    Revista de Neurologia, Vol. 59, Núm. 8, pp. 371-379

  4. Revisión de las novedades presentadas en el xxix congreso del comité europeo para el tratamiento e investigación en esclerosis múltiple (ECTRIMS) (I)

    Revista de Neurologia, Vol. 59, Núm. 6, pp. 269-280

2013

  1. Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

    Revista de Neurologia, Vol. 57, Núm. 5, pp. 217-229